• Abstract and Figures
• Public Full-text

THIS DOCUMENT AND ANY ACCOMPANYING DOCUMENTS ARE IMPORTANT AND REQUIRE YOUR IMMEDIATE ATTENTION. If you are in any doubt as to what action you should take, you are recommended to consult immediately your stockbroker, bank manager, solicitor, accountant, fund manager or other appropriate independent financial adviser being, if you are resident in Ireland, an organisation or firm authorised or exempted pursuant to the European Communities (Markets in Financial Instruments) Regulations (Nos. 1 to 3) 2007 or the Investment Intermediaries Act 1995 (as amended) and, if you are resident in the United Kingdom, a firm authorised under the Financial Services and Markets Act 2000 or from another appropriately authorised adviser if you are in a territory outside Ireland or the United Kingdom. If you sell or have sold or have otherwise transferred all of your Existing Ordinary Shares (other than ex-rights) in certificated form before 8.00 a.m. on 4 March 2009 (the “Ex-Rights Date”) please send this Prospectus and any other documents issued by the Company in connection with the Rights Issue, if and when received, at once to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for delivery to the purchaser or transferee except that such documents should not be sent to any jurisdiction where to do so might constitute a violation of local securities laws or regulations, including but not limited to any Excluded Territories. If you sell or have sold or have otherwise transferred all or some of your Existing Ordinary Shares (other than ex-rights) held in uncertificated form before the Ex- Rights Date, a claim transaction will automatically be generated by Euroclear which, on settlement, will transfer the appropriate number of Nil Paid Rights to the purchaser or transferee. If you sell or have sold or have otherwise transferred only some of your Existing Ordinary Shares (other than ex-rights) held in certificated form before the Ex-Rights Date, you should refer to the instruction regarding split applications in Part IX (Terms and Conditions of the Rights Issue) and in the Provisional Allotment Letter. The distribution of this Prospectus or any other documents issued by the Company in connection with the Rights Issue and the transfer of Nil Paid Rights, Fully Paid Rights and New Ordinary Shares into jurisdictions other than Ireland and the United Kingdom may be restricted by law and therefore persons into whose possession this Prospectus, or any other documents issued by the Company in connection with the Rights Issue, comes should inform themselves about and observe such restrictions. Any failure to comply with any such restrictions may constitute a violation of the securities laws or regulations of such jurisdictions. In particular, subject to certain exceptions, this Prospectus or any other documents issued by the Company in connection with the Rights Issue should not be distributed, forwarded to or transmitted in any Excluded Territories. All Overseas Shareholders and any person (including, without limitation, agents, custodians, nominees or trustees) who has a contractual or other legal obligation to forward this Prospectus or any other documents issued by the Company in connection with the Rights Issue, if and when received, to a jurisdiction outside Ireland or the United Kingdom should read section 3 of Part IX (Terms and Conditions of the Rights Issue). This Prospectus has been drawn up in accordance with Part 5 of the Investment Funds, Companies and Miscellaneous Provisions Act 2005 of Ireland, the Irish Prospectus Regulations, and the EU Prospectus Regulation. This Prospectus has been approved by the Irish Financial Services Regulatory Authority (the “Financial Regulator”), as competent authority under the Prospectus Directive 2003/71/EC. The Financial Regulator only approves this Prospectus as meeting the requirements imposed under Irish and EU law pursuant to the Prospectus Directive 2003/71/EC. Such approval relates only to the New Ordinary Shares which are to be admitted to trading on the regulated market of the Irish Stock Exchange or other regulated markets for the purposes of Directive 2004/39/EC or which are to be offered to the public in any member state of the European Economic Area. This Prospectus has been made available to the public in Ireland in accordance with Part 8 of the Irish Prospectus Regulations by the same being made available, free of charge, in electronic form on the Company’s website www.crh.com and in printed format until 11.00 a.m. on 18 March 2009 at the Company’s registered office, at the registered office of Capita Registrars and at the registered offices of the Underwriters, details of which are set out in Part VI (Directors, Company Secretary, Registered Office and Advisers). Copies of this Prospectus can also be obtained by Qualifying Shareholders by calling the Shareholder Helpline to request a copy. The Company has requested that the Financial Regulator provides a certificate of approval and a copy of this Prospectus to the competent authority, for the purposes of Prospectus Directive 2003/71/EC, in the United Kingdom. The Ordinary Shares are listed on the Official Lists and are traded on the regulated markets for listed securities of the Irish Stock Exchange and the London Stock Exchange. Application has been made to the Irish Stock Exchange and the UK Listing Authority for 152,087,952 New Ordinary Shares, nil paid and fully paid, to be admitted to the Official Lists and application has been made to the Irish Stock Exchange and the London Stock Exchange for such New Ordinary Shares, nil paid and fully paid, to be admitted to trading on their respective regulated markets for listed securities. It is expected that such admission will become effective and that dealings will commence in the New Ordinary Shares, nil paid, at 8.00 a.m. on 4 March 2009. CRH plc (incorporated in Ireland under the Companies Acts with registered number 12965) 2 for 7 Rights Issue of 152,087,952 New Ordinary Shares at E8.40 each UBS Investment Bank Davy Joint Global Co-ordinators, Joint Bookrunners and Joint Sponsors Your attention is drawn to the letter from your Chairman which is set out in Part VII (Letter from the Chairman of CRH). You should read the whole of this Prospectus and any documents incorporated herein by reference (a list is set out in Part XVI (Documents Incorporated by Reference)). Qualifying Shareholders and any other persons contemplating a purchase of Nil Paid Rights, Fully Paid Rights or New Ordinary Shares should review the risk factors set out in Part II (Risk Factors) for a discussion of certain factors that should be considered when deciding on what action to take in relation to the Rights Issue and deciding whether or not to purchase Nil Paid Rights, Fully Paid Rights or New Ordinary Shares. This Prospectus is intended for use in connection with offers and sales of the Nil Paid Rights, the Fully Paid Rights, the Provisional Allotment Letters and the New Ordinary Shares outside the United States and any other Excluded Territory and must not be sent or given to any person within the United States or any other Excluded Territory. The Nil Paid Rights, the Fully Paid Rights, the Provisional Allotment Letters and the New Ordinary Shares have not been and will not be registered under the US Securities Act or under any securities laws of any state or other jurisdiction of the United States, or any other Excluded Territory, and may not be offered, sold, taken up, exercised, resold, renounced, transferred or delivered, directly or indirectly, within the United States or any other Excluded Territory, except pursuant to an applicable exemption from the registration requirements of the US Securities Act (in the case of the United States) and in compliance with any applicable securities laws of any state or other jurisdiction of the United States or any other Excluded Territory. There will be no public offer in the United States or in any other Excluded Territory. UBS Limited is acting exclusively for CRH, as joint sponsor for the purposes of the Listing Rules of the Irish Stock Exchange, sole sponsor for the purposes of the Listing Rules made by the FSA, joint global co-ordinator and joint bookrunner, and no one else in connection with the Rights Issue and will not regard any other person (including the recipients of this Prospectus) as a client in relation to the Rights Issue and will not be responsible to anyone other than the Company for providing the protections afforded to its customers or for providing advice in relation to the Rights Issue or any other matters referred to in this Prospectus. Apart from the responsibilities and liabilities, if any, which may be imposed by the FSMA, the Financial Regulator or any applicable Irish law, UBS Limited makes no representation, express or implied, with respect to the accuracy, verification or completeness of any information contained in this Prospectus and accepts no responsibility for, nor does it authorise, the contents of this Prospectus or its publication, including without limitation under section 41 of the Investment Funds, Companies and Miscellaneous Provisions Act 2005 or Regulation 31 of the Irish Prospectus Regulations, or any other statement made or purported to be made by the Company, or on its behalf, in connection with the Rights Issue, Admission, the New Ordinary Shares or any of the other arrangements described in this Prospectus, and accordingly disclaims all and any liability whatsoever whether arising out of tort, contract or otherwise which it might otherwise have to any person other than CRH in respect of this Prospectus or any other statement.

Load more

  212

Copy Link